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a b s t r a c t
Chronic low-grade inﬂammation during aging (inﬂammaging) is associated with cognitive decline and
neurodegeneration; however, the mechanisms underlying inﬂammaging are unclear. We studied a
population (n ¼ 361) of healthy young and old adults from the MyoAge cohort. Peripheral levels of C-X-C
motif chemokine ligand 10 (CXCL10) was found to be higher in older adults, compared with young, and
negatively associated with working memory performance. This coincided with an age-related reduction
in blood DNA methylation at speciﬁc CpGs within the CXCL10 gene promoter. In vitro analysis supported
the role of DNA methylation in regulating CXCL10 transcription. A polymorphism (rs56061981) that
altered methylation at one of these CpG sites further associated with working memory performance in 2
independent aging cohorts. Studying prefrontal cortex samples, we found higher CXCL10 protein levels in
those with Alzheimer’s disease, compared with aged controls. These ﬁndings support the association of
peripheral inﬂammation, as demonstrated by CXCL10, in aging and cognitive decline. We reveal age-
related epigenetic and genetic factors which contribute to the dysregulation of CXCL10.
 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Aging is associated with a heightened and prolonged systemic
inﬂammation, termed inﬂammaging (Baylis et al., 2013; Franceschi
and Campisi, 2014). The central nervous system (CNS) and pe-
ripheral immune system are inextricably linked and immunoreg-
ulatory signals support and shape the immune system (McAfoose
and Baune, 2009; Schwartz et al., 2013). Accumulating evidence
links chronic inﬂammation to cognitive decline and the risk of
dementia. For example, mice lacking an adaptive immune system
have reduced rates of neurogenesis (Ziv et al., 2006) and manifest
cognitive deﬁcits (Kipnis et al., 2004; Ziv et al., 2006). Furthermore,
through the use of aging heterochronic parabiosis mouse models,
excessive circulating proinﬂammatory cytokines in older organisms
have been linked to neuronal insults and impaired spatial learning
andmemory (Villeda et al., 2011). In humans, older adults with high
blood concentrations of proinﬂammatory cytokines perform worse
on certain cognitive assessments (Baune et al., 2008; Trollor et al.,
2012; Wilson et al., 2002) and are at an increased risk of
dementia (Koyama et al., 2013), compared to those with low
concentrations.
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The molecular mechanisms underlying inﬂammaging, and the
cognitive dysfunctions associated with it, are poorly understood.
Since heterogeneity in the immune system between individuals are
predominantly accountable by nonheritable inﬂuences (Brodin
et al., 2015), the augmented inﬂammaging response may be a
result of epigenetic disturbances. Epigenetics concernsmechanisms
which mediate genetic control without altering the underling DNA
sequence. DNA methylation, for example, is an epigenetic mediator
of gene repression, and aging has been shown to dysregulate
genome-wide DNA methylation marks (Jung and Pfeifer, 2015) and
has been linked to neurodegeneration (Lardenoije et al., 2015).
Here, we investigated a panel of 35 plasma cytokines in physi-
cally and mentally healthy young and older human adults to
identify age-related immune markers associated with speciﬁc
measures of cognition. This revealed one cytokine, C-X-C motif
chemokine ligand 10 (CXCL10), associated with spatial working
memory. We further identiﬁed epigenetic mechanisms controlling
age-related regulation of CXCL10, through DNA methylation at
speciﬁc CpGs in the promoter. We then tested the relationship of a
polymorphism, which removes one of these CpGs, with spatial
working memory performance. Finally, we investigated CXCL10
within brain samples obtained from deceased individuals with
pathological signs of intermediate Alzheimer’s disease (AD) and
compared them to aged controls.
2. Materials and methods
2.1. Study population
The study population analyzed was a part of the cross-sectional
European multi-centre MyoAge cohort (McPhee et al., 2013). Those
with full cognitive data and plasma samples available were
included in this analysis (n ¼ 361). Analysis consisted of young (n ¼
135) and relatively healthy older (n ¼ 226) participants (98.9%
Caucasian). A detailed description of the exclusion criteria,
designed to ensure the selection of healthy participants and to
minimize the confounding effect of comorbidity on sarcopenia, has
been reported previously (McPhee et al., 2013). Information
regarding lifestyle factors (such as education level, smoking status,
and excessive alcohol intake) were self-reported. Excessive alcohol
was deﬁned for men as >21 units/week and for women >14 units/
week. The local medical ethics committees of the respective in-
stitutions approved the study, and written informed consent was
obtained from all participants.
2.2. Cognitive assessment
Participants completed the MinieMental State Examination
(Folstein et al., 1975) and Geriatric Depression Scale (Yesavage et al.,
1982) questionnaires to screen for cognitive impairment and
depression, respectively. Exclusion criteria were set as; an Mini-
eMental State Examination score of 23 and/or a Geriatric
Depression Scale score of 5 points. Cognition (spatial working
memory, executive functioning, and episodic memory) were
assessed using the Cambridge Neuropsychological Test Automated
Battery system (Cambridge Cognition Ltd). In addition, a global
cognition score was determined as the sum of the 3 individual
outcomes to represent a combined performance as utilized previ-
ously (Bradburn et al., 2016). Detailed information regarding each
test and their output has been published previously (Bradburn
et al., 2016). Each cognitive output was standardized by trans-
forming into a Z-score based on the young group’s average. A
positive score therefore will indicate a higher than average per-
formance and vice versa.
2.3. Plasma cytokine quantiﬁcations
Fasted plasma cytokines were quantiﬁed using either cytokine
magnetic bead panels (MILLIPLEX MAP, Millipore; Supplementary
Table 1) or sandwich ELISA assays (interleukin (IL) -1Ra, IL-6, IL-
10, and tumor necrosis factor (TNF) -a; R&D Systems). For the
multiplex immunoassays, assays included an overnight incubation
at 4 C and the use of a magnetic platewasher (Bio-Tek ELx405; Bio-
Tek). Plates were processed on a Luminex 200 instrument (Lumi-
nex), and protein concentrations determined with the xPONENT
software (Luminex, v. 3.1.871).
2.4. Plasma biochemical markers
Fasted plasma glucose, triglycerides, total cholesterol, high-
density lipoprotein cholesterol and low-density lipoprotein
cholesterol were all measured using a Daytona biochemical
analyzer (Randox, County Antrim).
2.5. Blood cell counts
Lymphocyte and neutrophil counts were determined from
whole blood using the KX-21 Automated Hematology Analyzer
(Sysmex).
2.6. DNA extraction
Genomic DNA was extracted and puriﬁed from whole blood
(buffy coat), cell cultures, and brain tissue samples using the Isolate
II Blood DNA kit (Bioline), as per the manufacturer’s instructions.
2.7. DNA bisulﬁte pyrosequencing
Genomic DNA (1 mg) was bisulﬁte treated via the EpiTect Fast
Bisulﬁte Conversion kit (Qiagen). Primers were designed using the
PyroMark Assay Design 2.0 (Qiagen) software and sequences are
presented in Supplementary Table 2. The CXCL10 proximal pro-
moter region was ampliﬁed through polymerase chain reaction
(PCR) using the PyroMark PCR reagents (Qiagen) with the following
conditions: 95 C (15 minutes), [94 C (30 seconds), 56 C (30 sec-
onds), 72 C (30 seconds)] (50 cycles), 72 C (10 minutes). Bisulﬁte
pyrosequencing was performed on the PyroMark Q24 system
(Qiagen) as per the manufacturer’s recommendations. A bisulﬁte
conversion control was included in each sequencing assay to
conﬁrm complete bisulﬁte conversion of DNA.
2.8. Cell cultures
HeLa (ATCC) and U937 (ATCC) cells weremaintained in Dulbecco
Modiﬁed Eagle’s medium and Roswell Park Memorial Institute
medium 1640 media, respectively. Media were supplemented with
10% heat-inactivated FBS (Sigma), 2-mM L-glutamine (Lonza), and
200 U/mL Penicillin-Streptomycin (Lonza). Cells weremaintained at
37 C with 5% carbon dioxide.
2.9. Real-time polymerase chain reaction
Total RNA (2 mg) was extracted from U937 cells using TriSure
(Bioline) and reverse transcribed into cDNA using the Tetro cDNA
synthesis kit (Bioline) with the use of random hexamers. Primer
sequences are found in Supplementary Table 2. Real-time poly-
merase chain reaction (RT-PCR) was performed on the Stratagene
Mx3000P (Agilent) system using SYBR Green chemistry (SensiFAST
HI-ROX, Bioline). RT-PCR was performed with the following pro-
gram; 95 C (2 minutes), [95 C (5 seconds), 60 C (10 seconds), 72
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C (10 seconds)] (40 cycles). All samples were analyzed in duplicate
and the average cycle threshold value determined. Relative
messenger RNA gene expression was calculated with the 2DDCt
equation (Livak and Schmittgen, 2001) using GAPDH and ACTB as
internal controls.
2.10. CXCL10 promoter plasmid and in vitro methylation
The pGL4-CXCL10 plasmid was used, which contains the full-
length 972 bp human CXCL10 promoter (875 to þ97 bp of the
TSS), as created previously (Spurrell et al., 2005). The plasmid was
subject to in vitro methylation treatment by using the CpG meth-
yltransferase (M.SssI) enzyme (New England Biolabs), according to
the manufacturer’s instructions. For the unmethylated version,
nuclease-free H2O was used instead of the M.SssI methylase
enzyme. To methylate just the CXCL10 promoter within the plasmid
(patch methylation), the pGL4-CXCL10 plasmid (10 mg) was ﬁrst
double digested with KpnI-HF and NheI-HF (20 U each; New En-
gland Biolabs) restriction enzymes, and the products were gel
extracted and puriﬁed via the NucleoSpin Gel and PCR Clean-up kit
(Macherey-Nagel). The extracted CXCL10 promoter insert (2 mg) was
subject to the same aforementioned in vitro methylation treatment
and puriﬁed with the NucleoSpin Gel and PCR Clean-up kit. The
CXCL10 promoter insert (200 ng) was ligated back into the pGL4
backbone using the Quick-Stick Ligase Kit (Bioline) using a vector-
insert molar ratio of 1:4. Ligation efﬁciency was assessed by
running on an agarose gel. Methylation of the CpG sites within the
CXCL10 proximal promoter for each construct was validated by
bisulﬁte pyrosequencing.
2.11. Cell transfection and reporter assay
HeLa cells (0.5  104/mL (500 mL)) were co-transfected with
methylated or unmethylated pGL4-CXCL10 constructs and a pSV-b-
Galactosidase control vector (Promega) using Lipofectamine 3000
(Thermo Fisher) for 24 hours. Reaction mixtures contained either
500 ng of whole pGL4-CXCL10 constructs or 20 mL of ligated patch
methylation construct with 500 ng pSV-b-Galactosidase vector.
Cells were washed twice with Dulbecco’s phosphate-buffered sa-
line before the addition of 10 ng/mL TNF-a and IFN-g for 6 hours to
stimulate CXCL10 upregulation. Luciferase and b-galactosidase ac-
tivities were simultaneously assessed from the same aliquot of cell
lysate using the Dual-Light assay (Applied Biosystems). Lumines-
cence was measured using the Synergy HT microplate reader
(Bio-Tek) with automatic injectors used throughout. Assays were
performed in duplicate and an average value calculated. Trans-
fection normalization was performed by dividing the luciferase
signal by the b-galactosidase signal to account for transfection
efﬁciency. Results are presented as percentage activity relative to
the unmethylated plasmids (100% activity).
2.12. Genotyping
In total, 3 single nucleotide polymorphisms (SNPs) were geno-
typed: rs56061981 (CXCL10), rs7412 (APOE), and rs429358 (APOE).
The rs56061981 and rs7412 SNPs were simultaneously detected
using iPLEX technology by CIGMR Biobank (The University of
Manchester, UK), a fee-for-service provider, using the Sequenom
system. The rs429358 SNP was analyzed using a TaqMan assay
(Cat# 4351379; Thermo Fischer Scientiﬁc). The rs429358 and
rs7412 genotypes were used to determine the APOE ε4 allele fre-
quency (Belbin et al., 2007). The genotyping completion rate for the
SNPs was: 96.4% rs7412 (13 failures), 98.9% rs429358 (4 failures),
and 97.8% rs56061981 (8 failures).
2.13. Replicative genetic cohort
The University of Manchester Age and Cognitive Performance
Research Cohort (ACPRC), and the linked Dyne-Steele DNA archive
for cognitive genetics, were used as a replicate population for the
genetic analysis of the rs56061981 polymorphism with a similar
spatial working memory score as in the MyoAge cohort. Recruit-
ment methodology for the ACPRC has been described in detail
elsewhere (Rabbitt et al., 2004). Only those which contained data
on: rs56061981 genotype, spatial working memory performance,
age at testing and gender were included in this analysis (n ¼ 1493;
age ¼ 65.26  6.16 years; 71.1% female). Spatial working memory
performance from the ACPRC was measured by the memory circle
test, as described previously (Rabbitt et al., 2004). Brieﬂy, partici-
pants were shown a 12-quadrant circle containing a line drawing of
recognizable objects and asked to immediately recall the names
and the location of the objects. The number of object names and
their corresponding location successfully recalled is herein classed
as the spatial working memory score (12 maximum).
2.14. Prefrontal cortex samples
Fresh, frozen human prefrontal cortex samples (n ¼ 67) were
acquired from the Manchester Brain Bank of participants from the
ACPRC (Supplementary Table 3). Ethical approval was granted from
the Manchester Brain Bank Committee. Conﬁrmation of patholog-
ical diagnosis was determined by a trained pathologist and with the
use of immunohistochemical techniques. Where applicable, sam-
ples were stratiﬁed into 2 groups termed aged (Braak stage: 0eII;
CERAD:  A) and intermediate AD (Braak stage: IIIeIV; CERAD: B;
Thal stage: 1) (Supplementary Table 4). Samples which contained
potentially confounding pathologies, such as those related to Par-
kinson’s disease, were excluded from subgrouping.
2.15. CXCL10 protein brain lysate quantiﬁcation
Approximately 100 mg of tissue was used for CXCL10 protein
quantiﬁcation. Brieﬂy, tissues were lysed with RIPA buffer (Sigma)
supplemented with 1 protease inhibitor cocktail (Sigma) and 0.1-
M PMSF (Sigma). Total protein quantiﬁcation from lysates was
determined using the Pierce BCA Protein Assay Kit (Thermo Sci-
entiﬁc). Quantiﬁcation of lysate CXCL10 protein was determined
with the Human CXCL10/IP-10 DuoSet ELISA (R&D Systems).
CXCL10 levels were normalized relative to the total protein in the
assay (pg/mg of total protein).
2.16. Statistical analysis
All statistical analyses were performed using IBM SPSS Statistics
23 and the level of signiﬁcancewas set at p< 0.05, unless otherwise
stated. For population characteristics, normally distributed
continuous data were analyzed by independent Student t tests and
presented as mean  standard deviation. Otherwise, Mann-
Whitney U tests were performed and results were presented as
median and interquartile range. Categorical data were analyzed via
Pearson c2. Cytokine protein concentrations were natural log (ln)
transformed before analysis and compared using Mann-Whitney U
tests.
Based on a posteriori evidence, those cytokines which differed
between age groups were analyzed further through Spearman
partial correlations (1-tailed analysis) to control for gender,
participant location, and various confounding variables. A con-
founding variable was deﬁned if any of the anthropometry, lifestyle,
or cardiovascular health markers listing in Table 1 had a relation-
ship with the cytokines through a Spearman correlation at the
S. Bradburn et al. / Neurobiology of Aging 63 (2018) 54e6456
p < 0.1 level (2-tailed analysis), as used previously (Baune et al.,
2008; Bradburn et al., 2016; Wright et al., 2006). Owing to multi-
ple testing effects (17 tests), a Bonferroni corrected signiﬁcance
threshold of p < 0.003 (0.05/17) was also applied here.
To determine the relationship between age-related cytokines
and measures of cognitive performance in the older adults,
Spearman correlations (2-tailed analysis) were ﬁrst applied. Sig-
niﬁcant relationships were analyzed further through Spearman
partial correlations (1-tailed analysis) to determine if the relation-
ship between the cytokine concentration and cognition remained
after controlling for gender, participant location, age, education
level, and APOE ε4 presence. Owing to multiple testing effects (3
tests), a Bonferroni corrected signiﬁcance threshold of p < 0.017
(0.05/3) was applied.
Age differences for DNAmethylation at CpG sites between young
and old adults were performed using independent Student t tests.
Correlations between CpG site methylation levels were determined
with Pearson’s correlation tests. Age correlations with DNA
methylation, while controlling for white blood cell populations
(neutrophil and lymphocyte percentages), were performed using
Spearman partial correlations.
Comparisons between control and stimulated cell culture
models were determined with independent Student t tests. Dif-
ferences in CXCL10 promoter activity was calculated with Mann-
Whitney U tests.
Relationships between the rs56061981 polymorphism and
spatial working memory scores were assessed through separate
linear regression models (additive and dominant) using the PLINK
software (v.1.90b3.36). Models included adjustments for age at
testing and gender (and participant location for the MyoAge
cohort). A positive standardized coefﬁcient (b) indicates the minor
allele increases the spatial working memory performance mean
and vice versa.
Correlations between CXCL10 DNA methylation and protein in
prefrontal cortex samples with age were analyzed with Spearman
correlation. Differences in methylation between genotypes and
protein levels between controls and those with intermediate AD
neuropathologies were conducted with Mann-Whitney U tests.
3. Results
To investigate age-related interactions between inﬂammation
and aging, we studied a cohort of physiologically and cognitively
healthy individuals as part of the MyoAge study (McPhee et al.,
2013). These were age stratiﬁed into 2 groups, young (range:
18e30 years) and old (range: 69e81 years). Their characteristics are
presented in Table 1.
3.1. Age-related differences in cytokines between healthy young and
old
Plasma concentrations of 35 inﬂammatory cytokines were
measured in the young and old groups. Seventeen (49%) of the
cytokines measured were signiﬁcantly different between the age
groups (Fig. 1). However, when controlling for gender, participant
location, and various predetermined confounding variables
through nonparametric partial correlation analysis, only CXCL10,
eotaxin-1, and IL-6 remained signiﬁcantly associated with partici-
pant ages (Supplementary Table 5).
Table 1
Characteristics of the MyoAge cohort used within this analysis
Variable Young Old p value
Age, y 23.42 (2.74) 74.47 (3.38) <0.001
Females, n (%) 71 (52.6) 116 (51.3) 0.816 (X2, 1 ¼ 0.05)
Location, n (%)
Holland 33 (24.4) 71 (31.4) 0.223 (X2, 4 ¼ 5.70)
Finland 34 (25.2) 68 (30.1)
Estonia 33 (24.4) 47 (20.8)
France 17 (12.6) 17 (7.5)
UK 18 (13.3) 23 (10.2)
Anthropometry
Height, m 1.74 (0.09) 1.68 (0.09) <0.001
Body mass, kg 68.95 (11.40) 71.45 (12.32) 0.055
BMI, kg/m2 22.71 (2.76) 25.36 (3.35) <0.001
Lifestyle
Current smoker, n (%) 14 (10.4) 11 (4.9) 0.046 (X2, 1 ¼ 3.97)
Excessive alcohol use, n (%) 15 (11.1) 19 (8.4) 0.395 (X2, 1 ¼ 0.72)
Cardiovascular health
Glucose, mmol/L 4.89 (0.57) 5.38 (0.77) <0.001
Triglyceride, mmol/L 0.92 (0.44) 1.14 (0.49) <0.001
Total cholesterol, mmol/L 4.37 (0.92) 5.36 (0.97) <0.001
HDL cholesterol, mmol/L 1.49 (0.40) 1.65 (0.40) <0.001
LDL cholesterol, mmol/L 2.50 (0.80) 3.18 (0.87) <0.001
Educationa
Basic school, n (%) 0 (0) 33 (17.8) <0.001 (X2, 2 ¼ 66.91)
High school, n (%) 14 (12.3) 70 (37.8)
University, n (%) 100 (87.7) 82 (44.3)
Mental state
MMSE score (points), median (IQR)b 30 (29e30) 29 (28e30) <0.001
GDS score (points), median (IQR)c 0 (0e1) 1 (0e2) 0.001
APOE genotyped
One or more APOE ε4 alleles present, n (%) 40 (30.1) 46 (21.3) 0.065 (X2, 1 ¼ 3.42)
All of the data presented are the mean (standard deviation), unless otherwise stated.
Key: GDS, Geriatric Depression Scale; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MMSE, MinieMental State Examination.
a Data available in n ¼ 299 (young, n ¼ 114; old, n ¼ 185).
b Data available in n ¼ 357 (young, n ¼ 134; old, n ¼ 223).
c Data available in n ¼ 316 (young, n ¼ 116; old, n ¼ 200).
d Data available in n ¼ 349 (young, n ¼ 133; old, n ¼ 216).
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3.2. Relationship between age-related cytokines and measures of
cognitive performance in the older adults
To determine whether any cytokines might associate with
cognition and age, those cytokines which were signiﬁcantly asso-
ciated with age were tested using Spearman correlation with the 4
cognitive performance scores in the older adults. Supplementary
Table 6 displays the correlation coefﬁcients for each relationship.
CXCL10 was negatively associated with spatial working memory,
and eotaxin-1 was negatively associated with episodic memory and
global cognition scores.
To further account for confounders, we next used nonpara-
metric partial correlation analysis to control for participant age,
gender, location, education level, and APOE ε4 allele presence.
Only the relationship between CXCL10 and spatial working
memory remained after adjustments (Table 2). This association
remained when BMI was also introduced as a confounder
(rhoadjusted ¼ 0.237, p ¼ 0.014).
3.3. DNA methylation at the CXCL10 proximal promoter in aging
and its association with plasma protein levels
We next investigated whether epigenetic changes in DNA
methylation occur at the CXCL10 gene with age, and whether this
might relate to the age-associated regulation of plasma CXCL10
levels. In a random subset of participants, DNAmethylation of the 3
CpG sites within the proximal CXCL10 promoter (Fig. 2A) were
quantiﬁed from blood samples via bisulﬁte pyrosequencing. DNA
methylation was signiﬁcantly lower in the older adults in compar-
ison to the younger adults at all 3 CpG sites investigated (CpG-168,
CpG-136 and CpG-8) (Fig. 2B).
Relationships between each CpG site were investigated to
determine if they are regulated together. There was a signiﬁcant
positive association between methylation at sites closest in prox-
imity, that is, CpG-168 and CpG-136 (r¼ 0.381, p< 0.001) as well as
CpG-136 and CpG-8 (r ¼ 0.624, p < 0.001).
To test whether levels of CpG methylation might critically relate
to cell heterogeneity within the samples, we next investigated the
relationship between average CpG methylation at the proximal
CXCL10 promoter with age while controlling for white blood cell
population changes (neutrophil and lymphocyte percentages).
Analysis revealed a negative correlation between participant age
and average CpG methylation (rho ¼ 0.368, p < 0.001) which
remained after accounting for neutrophil and lymphocyte fre-
quencies in the blood (rhoadjusted ¼ 0.212, p ¼ 0.032).
Spearman correlation analysis was also used to deduce the
possible relationships between CXCL10 promoter methylation and
CXCL10 plasma protein levels. A signiﬁcant negative association
between plasma CXCL10 protein with CpG-168 (Fig. 2C) and CpG-8
(Fig. 2E) was found. No association was found with CpG-136
(Fig. 2D). After controlling for participant age, only the relation-
ship between CpG-168 methylation with CXCL10 plasma protein
levels remained (rhoadjusted ¼ 0.255, p ¼ 0.002).
3.4. DNA methylation and regulation of CXCL10 promoter activity
To investigate whether DNA methylation at the CXCL10 pro-
moter regulates activity, we used in vitro systems. CXCL10
Fig. 1. Plasma cytokines which were signiﬁcantly different between the young and old adult group. (A) Plasma cytokines which were signiﬁcantly higher in the older adult group
compared to the younger adult group. (B) Plasma cytokines which were signiﬁcantly lower in the older adult group compared to the younger adult group. Young n ¼ 44e135; old n ¼
64e225. *p < 0.05; **p < 0.01; ***p < 0.001.
Table 2
Partial correlation between age-related plasma cytokines and cognition after con-
trolling for multiple confounders in the older adults
Relationship Adjusted correlation
coefﬁcient (rho)
p value
CXCL10 and spatial working memory 0.250 0.010a
Eotaxin-1 and episodic memory 0.168 0.060
Eotaxin-1 and global cognition 0.174 0.054
Controlling for: age, gender, location, education, and APOE ε4 allele presence.
One-tailed analysis; n ¼ 85.
Key: CXCL10, C-X-C motif chemokine ligand 10.
a Signiﬁes that the correlation is signiﬁcant after accounting for multiple testing
via the Bonferroni correction method (p < 0.017).
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transcription is activated in monocytes through synergistic induc-
tion by TNF-a and interferon (IFN) -g (Qi et al., 2009). Simulating
U937 cells (a human monocyte-like cell line) with TNF-a and IFN-g
resulted in a 1000-fold upregulation of CXCL10 messenger RNA
(Fig. 3A). However, this did not alter DNAmethylation at the CXCL10
proximal promoter (Fig. 3B).
We then tested the effects of DNA hypomethylation on CXCL10
promoter activity by incubating U937 cells with the DNA methyl-
transferase inhibitor 5-azacytidine (5-Aza) for 72 hours. Prior
optimization determined that 0.65-mM 5-Aza was the half inhibi-
tory concentration (IC50) of cell viability in U937 cells; therefore this
concentration was used during the experiment (Fig. 3C). 5-Aza
treatment induced a signiﬁcant reduction in DNA methylation at
each of the CpG sites within the CXCL10 proximal promoter region
(Fig. 3D). Testing CXCL10 gene activity, we found that before cell
stimulation, those incubated with 5-Aza had a twofold reduction in
CXCL10 gene expression (Fig. 3E). Following the stimulation with
TNF-a and IFN-g, those cells pre-incubated with 5-Aza produced a
twofold augmented CXCL10 gene induction when compared with
those without 5-Aza (Fig. 3E).
To understand the effect of DNA hypermethylation on CXCL10
promoter activity, we usedM.SssI methyltransferase to methylate a
plasmid construct containing the full human CXCL10 promoter re-
gion and transfected these into the HeLa cells. Methylation in vitro
was conducted on either the entire pGL4-CXCL10 plasmid or just
the CXCL10 full promoter region, which contains 7 CpGs in total
(Fig. 2A), through a patch methylation technique. Whole plasmid
methylation resulted in a 45% reduction of CXCL10 promoter ac-
tivity, whereas methylating just the CXCL10 promoter insert resul-
ted in a 10% reduction in promoter activity (Fig. 3F).
3.5. Relationship between rs56061981 polymorphism, DNA
methylation, and spatial working memory performance
We next investigated whether a polymorphism (rs56061981),
that effectively removes the CpG-136 site through a guanine (G) to
adenine (A) substitution (Fig. 4A), could inﬂuence CXCL10 promoter
methylation and in turn relate to cognition. Speciﬁcally, we
focussed on spatial working memory since CXCL10 protein levels
were signiﬁcantly associated with this particular cognitive
measure.
Methylation at the CpG-136 site was signiﬁcantly lower in the
heterozygotes (GA) when compared to the wild-type homozygotes
(GG) in the old adults (Fig. 4B). AA homozygotes were not included
in the analysis as there was only one in our study population. There
was no difference in plasma CXCL10 levels (p ¼ 0.730) and
methylation at the CpG-168 (p ¼ 0.787) or CpG-8 (p ¼ 0.210) be-
tween the GG and GA genotypes.
We next tested if the rs56061981 polymorphism was related to
spatial working memory performance in the old adults by using a
Fig. 2. DNA methylation differences between age groups for the CXCL10 proximal promoter and associations with plasma protein concentrations. (A) Full-length human CXCL10
promoter region (negative strand shown). Transcription factor binding sites were predicted using MatInspector (core: >0.9; matrix similarity: optimized). CpG sites are represented
as a red beacon with the positions relative to the transcriptional start site (extended arrow) in base pairs. There are 4 and 3 CpG sites located in the distal and proximal regions
respectively. (B) Differences in CXCL10 proximal promoter methylation between young and old adults. Young n ¼ 69; old n ¼ 82. **p < 0.01; ***p < 0.001. Association between plasma
CXCL10 levels (ln transformed) with CpG-168 (C), CpG-136 (D), and CpG-8 (E) methylation levels. n ¼ 122. Abbreviations: AP-1, activating protein 1; CCAAT, CAT box; CEBP-a, CCAAT/
enhancer binding protein alpha; CEBP-b, CCAAT/enhancer binding protein beta; IRF, interferon regulatory factor; CXCL10, C-X-C motif chemokine ligand 10; ISRE, IFN-stimulatory
element; NF-kB, nuclear factor-kappa B; STAT, signal transducers and activators of transcription. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the Web version of this article.)
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Fig. 3. Analysis of CXCL10 regulation, DNA methylation, and promoter activity. (A) CXCL10 mRNA expression in U937 cells following stimulation with 10 ng/mL TNF-a and IFN-g for
90 minutes. Values are normalized to GAPDH and BACTIN expression. n ¼ 3. (B) DNA methylation from U937 cells for the 3 CpG sites following stimulation with TNF-a and IFN-g. n ¼
3. (C) The half inhibitory concentration of U937 cells exposed to 5-azacytidine (5-Aza). Cell viability was determined by the trypan blue exclusion method. Brieﬂy, U937 cells were
seeded at 1  105 in a 24-well plate overnight. The next day cells were incubated with various concentrations (0.1, 0.2, 1, 2, 5, and 10 mM) of 5-Aza for 72 hours. Fresh 5-Aza was
added every 24 hours. Red line indicates a cell viability of 50%. n ¼ 3. (D) DNA methylation from U937 cells treated with and without 5-Aza for the 3 CpG sites. Cells were incubated
with 0.65 mM 5-Aza for 72 hours, with fresh 5-Aza added every 24 hours, before stimulation. n ¼ 3. (E) CXCL10 mRNA expression in U937 cells pre-treated with 5-Aza before and
after the addition of TNF-a and IFN-g. Values are normalized to GAPDH and BACTIN expression. Simulated levels of CXCL10 mRNA gene expression are relative to their unstimulated
counterparts. n ¼ 3. (AeE) **p < 0.01; ***p < 0.001. (F) Promoter activity of the CXCL10 promoter following in vitro methylation. Schematics denote either plasmid methylation or
patch methylation techniques. Beacons represent methylated (red) or unmethylated (white) CpG’s. Luciferase values were normalized via the b-galactosidase signal to account for
transfection efﬁciency, and results are expressed as the promoter percentage activity relative to the unmethylated constructs (100% activity; red dotted line). n ¼ 4e5. *p < 0.05;
**p < 0.01 relative to corresponding unmethylated constructs. Abbreviations: CXCL10, C-X-C motif chemokine ligand 10; mRNA, messenger RNA; TNF, tumor necrosis factor.
(For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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linear regression analysis to adjust for participant age at testing,
gender, and subject location. This demonstrated a signiﬁcant posi-
tive association between the rs56061981 genotype and spatial
working memory scores in the additive and dominant genetic
models in the older adult group (Table 3). The low frequency of AA
homozygotes (n ¼ 1) did not allow to test recessive genetic models.
To substantiate this ﬁnding, we tested for an association between
rs56061981 genotype with a spatial working memory test from
ACPRC (Rabbitt et al., 2004). This replicative cohort again revealed a
similar signiﬁcant association between the rs56061981 genotype
and spatial working memory performance (Table 3).
3.6. CXCL10 promoter methylation and protein levels within
prefrontal cortex
To explore mechanisms underlying CXCL10 regulation in the
aging brain, we tested CXCL10 promoter methylation and protein
levels in brains, speciﬁcally prefrontal cortex samples from the
ACPRC. There was no correlation between CXCL10 proximal pro-
moter methylation (CpG-168: rho ¼ 0.136, p ¼ 0.274; CpG-136:
rho ¼ 0.059, p ¼ 0.637; CpG-8: rho ¼ 0.154, p ¼ 0.212) or
CXCL10 protein levels (rho ¼ 0.187, p ¼ 0.132) and age at death of
the subjects. Methylation at the CpG-136 site was signiﬁcantly
lower in the heterozygotes (GA) when compared with the wild-
type homozygotes (GG; Fig. 5A).
Next, based on neuropathological data, we stratiﬁed samples
into 2 groups: intermediate AD and aged controls. There was no
difference in DNA methylation at the CXCL10 proximal promoter
between the 2 groups (CpG-168: p ¼ 0.260; CpG-136: p ¼ 0.382;
CpG-8: p ¼ 1.000). Those classiﬁed as having intermediate AD had
signiﬁcantly higher CXCL10 protein levels in the prefrontal cortex
compared with the aged controls (Fig. 5B).
4. Discussion
The results of this study further support the role of inﬂammation
in cognitive aging. We found higher concentrations of numerous
proinﬂammatory cytokines in old, compared with young adults.
The cytokine CXCL10 was signiﬁcantly associated with a measure of
cognitive performance, speciﬁcally spatial working memory, in the
older adults. Examining regulatory mechanisms, we further
detected age-associated reductions of DNAmethylation at CpG sites
within the CXCL10 proximal promoter region in the blood. DNA
methylation at speciﬁc sites within this region was negatively
correlated with CXCL10 plasma concentrations. Using in vitro sys-
tems, we showed that DNA methylation within the CXCL10 pro-
moter represses expression. Further, an SNP within the promoter
region which removes a CpG site and reduces methylation, was
found to positively associate with spatial working memory in 2
independent cohorts of older adults. Finally, investigating the
possible role of CXCL10 regulation in the brain, we found higher
CXCL10 protein levels in prefrontal cortex samples of those showing
intermediate pathological signs of AD comparedwith aged controls.
Initially, we described higher plasma CXCL10, eotaxin-1, and IL-6
in the older adults, even when accounting for confounding factors.
These age-related associations are in agreement with ﬁndings from
previous aging cohorts (Antonelli et al., 2006; Stowe et al., 2010;
Villeda et al., 2011). Of these, only CXCL10 associated with cogni-
tive performance when accounting for confounders in the older
adults. Interestingly, plasma CXCL10 levels have been linked to
cognitive status in Parkinson’s disease (Rocha et al., 2014) and are
elevated in the cerebrospinal ﬂuid of mild cognitive impaired pa-
tients (Galimberti et al., 2006). Investigations using neuronal cell
cultures have suggested that excess CXCL10 can act as a neurotoxic
agent by promoting apoptosis, as demonstrated in human fetal
neuronal cell cultures (Sui et al., 2006), human cholinergic neurons
(van Marle et al., 2004), human brain vascular endothelial cells
(Wilson et al., 2013), and neuroglia (Wilson et al., 2013). Therefore,
from a pathological perspective, excessive exposure of the CNS to
CXCL10 may be detrimental for neuronal functioning and cognitive
performance.
Next, we found that DNA methylation at the CXCL10 proximal
promoter regionwas signiﬁcantly lower in the blood of older adults
when compared with the younger adults. This age-related
Fig. 4. DNA methylation differences between rs56061981 genotypes in the healthy
young and old adults. (A) Schematic representation of CXCL10 proximal promoter
showing the rs56061981 polymorphism and the resulting change in the CpG-136 site
(negative strand shown). (B) Difference between CpG-136 methylation in GG (n ¼ 65)
and GA (n ¼ 14) carriers in the old group. *p < 0.05. Abbreviation: CXCL10, C-X-C motif
chemokine ligand 10.
Table 3
Relationship between rs56061981 polymorphism and spatial working memory
performance in old adults
Cohort/genetic effect b 95% CI p value
Lower Upper
MyoAgea
Additive 0.13 0.00 0.26 0.050
Dominant 0.17 0.04 0.30 0.009
ACPRCb
Additive 0.09 0.04 0.14 <0.001
Dominant 0.09 0.04 0.14 <0.001
Confounders adjusted for: age at testing and gender (and participant location for the
MyoAge cohort).
Key: b, standardized beta coefﬁcient; ACPRC, The University of Manchester Age and
Cognitive Performance Research Cohort.
a The rs56061981 SNP was deemed to be within the Hardy-Weinberg equilibrium
(frequency: 201 (GG), 19 (GA), 1 (AA); p ¼ 0.393).
b The rs56061981 SNP was deemed to be within the Hardy-Weinberg equilibrium
(frequency: 1385 (GG), 107 (GA), 1 (AA); p ¼ 0.719).
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hypomethylation is also apparent in other inﬂammatory genes,
such as TNF-a (Gowers et al., 2011) and IL-1b (Cho et al., 2015), thus
further suggesting a contribution of DNA methylation loss in
inﬂammaging. Since buffy coat samples contain a heterogeneous
cell population, therefore potentially inﬂuencing DNA methylation
results (Reinius et al., 2012), we further conﬁrm that the age-related
hypomethylation is independent of the differences in the variabil-
ities of certain blood cell types (neutrophils and lymphocytes).
CXCL10 hypomethylation with age is also in agreement with a
previous methylation array study in aging monozygotic twins,
speciﬁcally a reduction of methylation at the CpG-168 site (ID:
cg14622819) with age was found (Fernández et al., 2015). In addi-
tion, the CpG-800 site (ID: cg23884076) within the distal promoter
region (not analyzed here) was also hypomethylated during aging
on the same array (Fernández et al., 2015). Collectively there seems
to be an age-related loss of DNA methylation within the CXCL10
promoter from the blood.
DNA methylation is a known gene repressor; though RNA
analysis could not be tested on the blood samples, we did ﬁnd a
negative association between DNA methylation at CpG-168 of the
CXCL10 proximal promoter with plasma proteins levels suggesting
some level of control over gene regulation. Interestingly, CpG-168 is
located within a nuclear factor-kappa B (NF-kB) binding site. NF-kB
is a transcriptional regulator involved in numerous pathways
related to inﬂammation, including cytokine production and
apoptosis (Hayden and Ghosh, 2012) and is a potent activator of
CXCL10 (Yeruva et al., 2008). Furthermore, DNA methylation within
these binding sites has been known to inhibit NF-kB binding
(Bednarik et al., 1991). Complementing this potential CXCL10 gene
regulation involving DNA methylation, through the use of a DNA
methyltransferase inhibitor (5-Aza), we observed a signiﬁcant
hypomethylation of the proximal promoter coinciding with an
aberrant CXCL10 upregulation following stimulation of cells with
TNF-a and IFN-g. These results are supportive to those of Peng et al.
who incubated primary ovarian cancer cells with 5-aza-20-deoxy-
cytidine, a deoxy derivative of 5-Aza, which resulted in the hypo-
methylation of an STAT-1 binding site upstream of the promoter
region and an exacerbated release of CXCL10 following IFN-g
stimulation (Peng et al., 2015). STAT-1 is required for IFN-
geinduced CXCL10 production in monocytes (Qi et al., 2009), and
STAT-1 binding afﬁnity has been shown to be directly inhibited
following DNA methylation (Chen et al., 2000). On the other hand,
by hypermethylating the CXCL10 promoter region in vitro, we
further show a 10% reduction in promoter activity therefore sug-
gesting that DNA methylation directly contributes to CXCL10 gene
inhibition. It is worth noting that methylating the whole plasmid
resulted in further promoter repression, most likely due to the
methylation of CpG sites within the backbone and luciferase gene.
Collectively, these results suggest that CXCL10 promoter hypo-
methylation may prime regulatory regions thereby augmenting
gene induction when stimulated. Furthermore, since DNA methyl-
ation of the full promoter only explained 10% of the promoter ac-
tivity, it is unlikely to be the sole contributor to CXCL10 regulation.
Other epigenetic meditators, such as histone modiﬁcations (Burke
et al., 2013; Coward et al., 2010; Peng et al., 2015) and chromatin
remodeling (Hudy et al., 2013), have also been shown to contribute
to the transcriptional control of CXCL10 and therefore may account
for the additional variance in promoter activity.
Importantly, the described inhibitory effects of DNAmethylation
on the CXCL10 regulation are all based on stimulated systems,
rather than basal conditions. Surprisingly, despite the hypo-
methylation of the proximal promoter region, we found a twofold
reduction in CXCL10 gene expression in unstimulated U937 cells
following 5-Aza treatment. Here, activating transcription factors
(e.g., NF-kB p65 and STAT-1) on the CXCL10 promoter should not be
present, therefore, it may be possible, therefore, that repressive
transcription factors are further downregulating CXCL10. For
example, an NF-kB repressing factor binding element is present
within the CXCL10 promoter and NF-kB repressing factor has been
shown to directly inhibit basal CXCL10 expression in monocytes
(Huang et al., 2013, 2014).
CpG-136 investigated here forms part of the polymorphism
rs56061981. This SNP has previously been shown to alter the
binding afﬁnity of nuclear proteins and augments CXCL10 expres-
sion and protein production (Deng et al., 2008). Also, these speciﬁc
types of SNPs associated with CpG sites have been shown to directly
inﬂuence local DNA methylation (Hellman and Chess, 2010). Based
on this evidence, we tested for differences in DNA methylation at
this site between genotypes and found a lower methylation of CpG-
136 in the heterozygotes in the blood (Fig. 4B) and brain (Fig. 5A).
We next investigated the relationship between the rs56061981
genotype and cognitive performance in the older adults. Since we
previously found a link between spatial working memory and
CXCL10 protein levels, we limited our investigations to this cogni-
tive measure in older adults. There was a positive association be-
tween spatial working memory performance and the rs56061981
genotype. This relationship was also apparent in a separate larger
aging cohort. Overall, these associations suggest a better spatial
working memory performance with the presence of the minor
allele, conferring polymorphic hypomethylation. Considering pre-
vious reports suggest an increase in gene activity in the rs56061981
carriers (Deng et al., 2008; Singh et al., 2017), the association of
better spatial working memory performance in those affected was
unexpected. However, it is worth noting that the prior functional
Fig. 5. Comparison of CXCL10 methylation and protein levels in the prefrontal cortex. (A) Difference between CpG-136 methylation in GG (n ¼ 61) and GA (n ¼ 5) carriers in the
prefrontal cortex samples. (B) CXCL10 protein levels from the prefrontal cortex samples of those showing intermediate pathological signs of AD and those with no neuropathologies.
Aged n ¼ 17; intermediate AD n ¼ 16. *p < 0.05; **p < 0.01. Abbreviations: AD, Alzheimer’s disease; CXCL10, C-X-C motif chemokine ligand 10.
S. Bradburn et al. / Neurobiology of Aging 63 (2018) 54e6462
evaluation of the rs56061981 genotype on CXCL10 activity was
based on IFN-g stimulated, rather than basal, peripheral mono-
nuclear cells (Deng et al., 2008). Further work is therefore needed to
elaborate on the association between rs56061981, methylation, and
spatial working memory performance in older adults particularly at
the cellular level.
By using prefrontal cortex samples from ACPRC (Rabbitt et al.,
2004), we were able to provide an insight into the regulation of
CXCL10 within the human brain. We failed to ﬁnd any relationship
between CXCL10 protein or methylation levels with the age at death
of the participants. This lack of association may be accounted for by
the smaller age range of participants investigated (range:
72e104 years old). A larger age range, particularly including sam-
ples from younger individuals, may be required to conﬁrm possible
age-related CXCL10 changes within the brain. We next investigated
differences in between a group with intermediate pathological AD
and nonpathological aged controls. The intermediate AD group had
signiﬁcantly higher levels of CXCL10 protein compared with the
aged, however, n differences in DNA methylation were observed.
This would suggest the increase in CXCL10 protein within the brain
during AD pathogenesis is independent of DNA methylation regu-
lation. It is worth mentioning, however, that our results are limited
to brain tissues, as opposed to cell-speciﬁc analysis, which may
have an inﬂuence on the methylation ﬁndings. The increase in
CXCL10 protein is in agreement with reports describing increased
CXCL10 staining, especially within astrocytes, in close proximity to
amyloid-b deposits (Xia et al., 2000). There is also evidence of an
increase in cerebral Cxcl10 gene expression (Krauthausen et al.,
2015) and protein levels, most notably by microglia (Krauthausen
et al., 2015) and astrocytes (Lai et al., 2013), in rodent AD models.
Interestingly, cerebrospinal ﬂuid levels of CXCL10 have been sug-
gested to peak at the time of clinical mild cognitive impairment to
AD conversion in humans (Brosseron et al., 2014). The associations
between CXCL10 proteinwithin the CNS and periphery during early
AD pathogenesis warrant the need for further investigations
around this important disease stage.
5. Conclusions
In summary, we showed that the inﬂammatory proﬁle is
signiﬁcantly altered by aging. The proinﬂammatory age-related
cytokine, CXCL10, was negatively correlated with spatial working
memory in community-dwelling older adults. The age-associated
upregulation of plasma CXCL10 coincided with a reduction in
leukocyte DNA methylation within the gene promoter region. Loss
of DNA methylation within this region resulted in an increased
CXCL10 promoter activity. An SNP shown to induce hypo-
methylation correlated with a better spatial working memory
performance in 2 separate populations of older adults. Finally,
higher protein levels were also observed in the prefrontal cortex of
those with intermediate pathological AD. This study suggests that
age-related polymorphic and epigenetic dysregulations of key in-
ﬂammatory genes, such as CXCL10, may be involved in inﬂam-
maging and neurodegeneration.
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